Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Closes $11 Million in Funding for Breast Cancer Clinical Trials (04 Feb 2013)

February 4, 2013 by Novian Health

CHICAGO – Novian Health, developer of Novilase® Breast Therapy, announced today that it has successfully completed a funding round totaling $11 million. iNetworks, LLC (Pittsburgh, Pa) led the round of Series A Preferred share financing, which also included prior and new investors.

Proceeds from the funding will primarily be used to conduct Novian’s multicenter clinical trials in the U.S., Britain and France on the use of nonsurgical Novilase Interstitial Laser Therapy (ILT) for treating breast cancer. Patient enrollment for the multicenter trials has already begun in the U.S. and will commence soon in Britain and France.

“This substantial commitment from iNetworks as the institutional lead, along with other investors, will foster continual research and growth leading to commercialization of the Novilase treatment, which could greatly benefit women who have early- stage breast cancer,” said Henry “Chip” Appelbaum, Novian Health’s President and CEO. “iNetworks has a deep understanding of oncology and breast cancer treatment issues. Their confidence in the application of Novilase ILT to early-stage disease underlines the promise of Novian’s approach.”

The multicenter studies follow a successful feasibility study conducted at Rush University Medical Center by Kambiz Dowlat, M.D. The multicenter studies will evaluate the rate of complete tumor ablation (destruction by laser) of breast cancers that are less than 2 centimeters. They will also comprehensively correlate the pathology of post–ablation lumpectomy specimens with MRI and ultrasound in detecting any residual tumor.

“We have long been impressed with the Novilase therapy, and we expect it to help pioneer major improvements in the treatment of early-stage breast cancer,” said Anthony M. Lacenere, Managing Director of iNetworks.

When applied to early‐stage breast cancer, Novilase ILT may provide women with an ablation option that could result in a lower rate of residual disease. That means fewer retreatments, a shorter recovery time, and minimal scarring and breast deformity. Novilase does not preclude any additional treatment such as radiation therapy and/or systemic adjuvant therapy, per standard of care.

Given the trend toward more precise, targeted cancer treatments, many women today expect less-invasive procedures. Just as needle-core breast biopsy now provides an alternative to surgical biopsy, Novilase ILT may be another option for breast cancer patients who are considering surgical lumpectomy.

Novian Health will also seek to close on an additional $2.5 million of funding authorized in the current round.

Resources:

*Availability of Novilase ILT in Europe and the U.S.
*Multicenter trial sites and publications about Novilase ILT
*Novilase ILT vs. lumpectomy

About Novilase

Novilase is a laser-based, minimally invasive device for destroying tumors. It provides an alternative to conventional surgery while preserving the patient’s options for additional procedures or adjunctive therapies. The image-guided outpatient procedure does not require general anesthetic or a hospital stay.

About Novian Health

Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors. Image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.

About iNetworks

Founded in 1999, iNetworks helps companies and entrepreneurs accelerate their solutions by providing capital and intellectual resources to solve critical problems. iNetworks focuses primarily on healthcare and life sciences businesses that develop breakthrough technologies to improve clinical outcomes for patients and save time, money, and resources for healthcare providers. Learn more at www.inetworksllc.com.

Download PDF

More from my site

  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)
  • Novian Health Venture Capital Activity in 1Q 2013 for Breast Cancer Clinical Trials (18 April 2013)Novian Health Venture Capital Activity in 1Q 2013 for Breast Cancer Clinical Trials (18 April 2013)
  • Novian Health President & CEO Interviewed by Med Device Insights (01 Dec 2014)Novian Health President & CEO Interviewed by Med Device Insights (01 Dec 2014)
  • Qualifying Therapeutic Discovery Project GrantQualifying Therapeutic Discovery Project Grant
  • Novian Health Announces Agreement with Rose Medical Center in DenverNovian Health Announces Agreement with Rose Medical Center in Denver
  • Novian Health Presents at the “Investment in Innovation (IN3) Medical Device Summit: A Preview of Early-Stage Medical Technology Companies”TMNovian Health Presents at the “Investment in Innovation (IN3) Medical Device Summit: A Preview of Early-Stage Medical Technology Companies”TM

Filed Under: Press Release 2013

Recent Posts

  • Breast Cancer Clinical Trial of Laser Ablation Treatment Shows Promising Results for Patients (10 Dec 2015)
  • Novian Health President & CEO Interviewed by Med Device Insights (01 Dec 2014)
  • Walter Reed Bethesda Joins Novilase Clinical Trial (9 Sept 2014)
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors (2 Sept 2014)
  • Novian Health Named Finalist for the 2014 Red Herring Top 100 North America Award (16 May 2014)

ARCHIVES

  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015

CONTACT US

Address: 430 West Erie Street, Suite 500
Chicago, Illinois 60654
Office: 312-266-7200
Fax: 312-266-7202
Email: info@novianhealth.com

    

LATEST NEWS

  • Breast Cancer Clinical Trial of Laser Ablation Treatment Shows Promising Results for Patients (10 Dec 2015)
  • Novian Health President & CEO Interviewed by Med Device Insights (01 Dec 2014)
  • Walter Reed Bethesda Joins Novilase Clinical Trial (9 Sept 2014)

Copyright © 2019 Novian Health. All Rights Reserved. Powered by